Long-acting Injectable Medications Research:CAGR of 11.6% during the forecast period

QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report "Long-acting Injectable Medications- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031". Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2025-2031), this report provides a comprehensive analysis of the global Long-acting Injectable Medications market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Long-acting Injectable Medications was estimated to be worth US$ 10259 million in 2024 and is forecast to a readjusted size of US$ 21258 million by 2031 with a CAGR of 11.6% during the forecast period 2025-2031.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5444447/long-acting-injectable-medications

Long-acting Injectable Medications Market Summary

Long-acting injectables (LAIs) are unique tools used in psychiatric pharmacy to help improve patient outcomes. They offer a number of benefits compared to oral therapy, including confirmed patient adherence, consistent drug delivery, predictable bioavailability and prevention of antipsychotic overdoses. Its origins in indications such as schizophrenia and contraception, also HIV treatment and prevention.

LAIs include: Abilify Maintena®, Aristada®, Haldol decanoate®, Invega Hafyera®, Invega Sustenna®, Invega Trinza®, Risperdal Consta®, Perseris®, Uzedy® etc. The LAI can last anywhere from 2-24 weeks with just one dose, which mainly helps to control symptoms of mental illness.

The increasing global burden of chronic diseases-such as schizophrenia, bipolar disorder, diabetes, and opioid dependence-drives demand for long-acting injectable medications (LAIs). These formulations improve treatment adherence, reduce relapse rates, and provide more stable therapeutic outcomes compared with oral medications, which is especially valuable in long-term psychiatric and endocrine care.

Continuous innovation in sustained-release technologies-such as biodegradable microspheres, in-situ forming gels, and nanoparticle carriers-has expanded the scope of LAI development. These technologies enhance pharmacokinetic control, extend dosing intervals, and improve patient comfort, making LAIs more competitive against daily oral regimens.

According to the new market research report "Global Long-acting Injectable Medications Market Report 2025-2031", published by QYResearch, the global Long-acting Injectable Medications market size is projected to reach USD 21.26 billion by 2031, at a CAGR of 11.6% during the forecast period.

Figure00001. Global Long-acting Injectable Medications Market Size (US$ Million), 2019-2031

Long-acting Injectable Medications

Above data is based on report from QYResearch: Global Long-acting Injectable Medications Market Report 2025-2031 (published in 2025). If you need the latest data, plaese contact QYResearch.

Figure00002. Global Long-acting Injectable Medications Top 11 Players Ranking and Market Share (Ranking is based on the revenue of 2024, continually updated)

Long-acting Injectable Medications

Above data is based on report from QYResearch: Global Long-acting Injectable Medications Market Report 2025-2031 (published in 2025). If you need the latest data, plaese contact QYResearch.

According to QYResearch Top Players Research Center, the global key manufacturers of Long-acting Injectable Medications include Johnson & Johnson, Otsuka, GSK, Alkermes, Teva Pharmaceuticals, Eli Lilly, Luye Pharma, Neuraxpharm, Mapi Pharma, Lupin, etc. In 2024, the global top 10 players had a share approximately 75.0% in terms of revenue.

Figure00003. Long-acting Injectable Medications, Global Market Size, Split by Product Segment

Long-acting Injectable Medications

Based on or includes research from QYResearch: Global Long-acting Injectable Medications Market Report 2025-2031.

In terms of product type, currently Second Generation is the largest segment, hold a share of 94.3%.

In terms of product application, currently Schizophrenia is the largest segment, hold a share of 72.4%.

The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.

The Long-acting Injectable Medications market is segmented as below:
By Company
Johnson & Johnson
Otsuka
GSK
Eli Lilly
Alkermes
Teva Pharmaceuticals
Mapi Pharma
Lupin
Amneal
Neuraxpharm
Luye Pharma

Segment by Type
Second Generation
First Generation

Segment by Application
Schizophrenia
Bipolar Disorder
HIV
Diabete
Others

Each chapter of the report provides detailed information for readers to further understand the Long-acting Injectable Medications market:

Chapter 1: Introduces the report scope of the Long-acting Injectable Medications report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2020-2031)
Chapter 2: Detailed analysis of Long-acting Injectable Medications manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2020-2025)
Chapter 3: Provides the analysis of various Long-acting Injectable Medications market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2020-2031)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2020-2031)
Chapter 5: Sales, revenue of Long-acting Injectable Medications in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2020-2031)
Chapter 6: Sales, revenue of Long-acting Injectable Medications in country level. It provides sigmate data by Type, and by Application for each country/region.(2020-2031)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2020-2025)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Benefits of purchasing QYResearch report:

Competitive Analysis: QYResearch provides in-depth Long-acting Injectable Medications competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.

Industry Analysis: QYResearch provides Long-acting Injectable Medications comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.

and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.

Market Size: QYResearch provides Long-acting Injectable Medications market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.

Other relevant reports of QYResearch:
Global Long-acting Injectable Medications Market Outlook, In‐Depth Analysis & Forecast to 2031
Global Long-acting Injectable Medications Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Global Long-acting Injectable Medications Market Research Report 2025
Long-acting Injectable Medications- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

About Us:
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

This release was published on openPR.